Table 3.

Association analysis results for unadjusted and adjusted models of T2D exposure and UF risk limiting to subjects on specific treatments

	N	Crude				Adjusted
		ORT2D	95% CI		P	ORT2D	95% CI		P
			Lower	Upper			Lower	Upper
All Races
T2D (diabetics on Metformin)	3,435	1.12	0.84	1.48	0.450	0.77	0.56	1.05	0.096
T2D (diabetics on Thiazolidinedione)	3,208	1.36	0.86	2.08	0.161	0.91	0.56	1.48	0.708
T2D (diabetics on insulin)	3,481	0.71	0.52	0.97	0.032	0.50	0.35	0.70	5.10×10 −5
European American
T2D (diabetics on Metformin)	2,250	0.97	0.65	1.44	0.863	0.70	0.45	1.08	0.104
T2D (diabetics on Thiazolidinedione)	2,084	1.43	0.85	2.43	0.181	0.91	0.51	1.64	0.757
T2D (diabetics on insulin)	2,292	0.60	0.38	0.95	0.020	0.42	0.26	0.68	3.54×10 −4
African American
T2D (diabetics on Metformin)	755	1.07	0.68	1.69	0.760	0.78	0.47	1.28	0.329
T2D (diabetics on Thiazolidinedione)	669	1.24	0.56	2.76	0.597	0.77	0.32	1.90	0.581
T2D (diabetics on insulin)	764	0.76	0.47	1.22	0.260	0.60	0.36	1.01	0.055

T2D type 2 diabetes, BMI body mass index, OR Odds ratio, CI 95% confidence interval; Bold indicates models with p < 0.05; Adjusted models use age (continuous), BMI (continuous); Bold indicates models with p < 0.05; N-samples size of total number of cases and controls within each drug category